Worldwide Prosthetic Heart Valve Market to 2025

January 27, 2021

Worldwide prosthetic heart valve market will show rapid growth due to the subsequent growth in the prevalence of heart valve disease and rising regulatory approvals for a new and advanced prosthetic heart valve.

Valvular heart disease (VHD) places a significant burden on the global healthcare system. According to the American College of Cardiology, there are approximately 5 million Americans that are being diagnosed with HVD every year. VHD mainly affects the older population as a result of calcium buildup and scarring in the valve cusp due to ageing. The prevalence of VHD in the population aged 18-44 and 75 years was 0.7% and 13.0%, respectively in 2012. Therefore the rapid growth in the ageing population and the consequent rise in the prevalence of VHD is expected to drive the market growth for the prosthetic heart valve market.

The prosthetic valves market has also witnessed several clinical trials in recent years especially in the European countries due to uniform regulations and high prevalence of heart diseases.

Companies Mentioned

  • Medtronic PLC
  • Edwards Lifesciences Corporation
  • Boston Scientific Corporation
  • Livanova PLC
  • St. Jude Medical Inc. (An Abbott Laboratories Company)
  • Symetis SA
  • Jenavalve Technology Inc.
  • Cryolife Inc.
  • TTK Healthcare Limited
  • Colibri Heart Valve LLC
  • Lepu Medical Technology Co. Ltd

Key Market Trends

Transcatheter Heart Valve Segment is Expected to Register Robust Growth During the Forecast Period

The transcatheter heart valve segment is expected to hold a significant share in the global market and the large share can be attributed to the various factors such as ease of implantation, rise in the number of transcatheter heart valve surgery centres and growing of the patient population. There are also growth opportunities in emerging countries and the use of transcatheter heart valves for new indications (treatment of intermediate-risk patients and high-risk patients) are thus expected to provide numerous opportunities for the market growth during the forecast period.

In addition, the rise in adoption rate for transcatheter heart valve implantation procedure and new device approvals are expected to lead the growth of transcatheter heart valve market.

North America is Found to be the Largest Market for the Prosthetic Heart Valve

North America is expected to dominate the prosthetic heart valve market, followed by Europe, Asia-Pacific, and the rest of the world. North America contributes to the largest market share due to the rapid growth in the ageing population and the high prevalence of valvular heart diseases. Furthermore, the favourable reimbursement scenario and rising product approvals for the heart valve are also contributing to the growth of the North American prosthetic heart valve market.

The Asia Pacific is also expected to witness the high growth in the next few years, due to the growing incidences of chronic diseases and increasing disposable income.

Competitive Landscape

A majority of the leading players in this market are focusing on marketing and promotional activities, product launches and approvals, acquisitions, agreements, collaborations, and expansions to enhance their market presence and strengthen their distribution networks, cater to the needs of a growing customer base, widen their product portfolios, and boost their production capabilities.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Prevalence of Heart Valve Disease

4.2.2 Rising Regulatory Approvals for New and Advanced Prosthetic Heart Valve

4.3 Market Restraints

4.3.1 High Cost of Transcatheter Aortic Valve Replacement (TAVR) Procedures

4.3.2 Availability of Alternative Methods for Treating Heart Valve Diseases (HVD)

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Type of Valve

5.1.1 Mechanical Heart Valve

5.1.2 Bioprosthetic Heart Valve

5.1.3 Transcatheter Heart Valve

5.2 By Position

5.2.1 Mitral Valve

5.2.2 Aortic Valve

5.2.3 Other Positions

5.3 Geography

5.3.1 North America

5.3.2 Europe

5.3.3 Asia-Pacific

5.3.4 Middle East & Africa

5.3.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”